FTSE MIB
33.675,59 -60,81 (-0,18%) Dow Jones
38.655,84 +430,18 (+1,13%) Nasdaq
16.119,92 +278,96 (+1,76%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
78,78 -0,17 (-0,22%) Bitcoin EUR
57.070,70 +2.770,85 (+5,10%)
GILD Jun 2024 70.000 put
| Chiusura precedente | 5,30 |
| Aperto | 5,55 |
| Denaro | 0,00 |
| Lettera | 0,00 |
| Prezzo d'esercizio | 70,00 |
| Scadenza | 2024-06-21 |
| Min-Max giorno | 5,30 - 5,70 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 3,52k |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr
